Shire’s retinopathy treatment fails to meet primary endpoint in phase 2 trial
The phase 2 study included 121 extremely premature infants born before 28 weeks’ gestation who were randomized to receive SHP607 or standard neonatal care and were treated until
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.